Bill > S08780

This bill requires that certain kratom products, which are derived from the Mitragyna speciosa plant or its synthesized compounds, must include specific warning labels. These labels must disclose the manufacturer's or distributor's information, a full list of ingredients, and several important advisories, including that sales to individuals under twenty-one are prohibited, use by pregnant or breastfeeding individuals is not advised, and consumers should consult a healthcare professional before use. Crucially, the labels must state that kratom may be addictive and can interact with other medications, drugs, and controlled substances. The bill also mandates disclosure if the product contains semi-synthesized or synthesized chemicals of kratom, with definitions provided for these terms, and requires quantitative declarations of mitragynine and 7-hydroxymitragynine content. Additionally, the labels must include a statement that the product has not been evaluated by the Food and Drug Administration (FDA) and is not intended to diagnose, treat, cure, or prevent any disease, along with a clear warning to keep the product out of reach of children. Violators will face civil penalties.

https://www.nysenate.gov/legislation/bills/2025/S8780